Abivax SA American Depositary Shares
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as … Read more
Abivax SA American Depositary Shares (ABVX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.139x
Based on the latest financial reports, Abivax SA American Depositary Shares (ABVX) has a cash flow conversion efficiency ratio of -0.139x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-71.28 Million) by net assets ($511.24 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Abivax SA American Depositary Shares - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Abivax SA American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Abivax SA American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Abivax SA American Depositary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ricoh Company Ltd
PINK:RICOY
|
0.047x |
|
Hotai Motor Co Ltd
TW:2207
|
0.112x |
|
Zhejiang China Commodities City Group Co Ltd
SHG:600415
|
0.369x |
|
Colliers International Group Inc Bats
NASDAQ:CIGI
|
0.040x |
|
Travel + Leisure Co
NYSE:TNL
|
-0.629x |
|
Galaxy Digital Holdings Ltd
NASDAQ:GLXY
|
-0.338x |
|
Skyline Corporation
NYSE:SKY
|
0.063x |
|
HMM Co Ltd
KO:011200
|
0.041x |
Annual Cash Flow Conversion Efficiency for Abivax SA American Depositary Shares (2014–2024)
The table below shows the annual cash flow conversion efficiency of Abivax SA American Depositary Shares from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $40.58 Million | $-154.07 Million | -3.796x | -644.06% |
| 2023-12-31 | $196.01 Million | $-100.01 Million | -0.510x | +93.20% |
| 2022-12-31 | $7.19 Million | $-53.94 Million | -7.503x | -326.14% |
| 2021-12-31 | $25.93 Million | $-45.66 Million | -1.761x | -5.67% |
| 2020-12-31 | $17.90 Million | $-29.82 Million | -1.666x | -12.75% |
| 2019-12-31 | $18.59 Million | $-27.47 Million | -1.478x | -250.67% |
| 2018-12-31 | $34.66 Million | $-14.60 Million | -0.421x | -140.29% |
| 2017-12-31 | $48.18 Million | $-8.45 Million | -0.175x | +36.28% |
| 2016-12-31 | $56.72 Million | $-15.61 Million | -0.275x | -32.51% |
| 2015-12-31 | $71.77 Million | $-14.90 Million | -0.208x | -113.23% |
| 2014-12-31 | $33.94 Million | $-3.31 Million | -0.097x | -- |